

Nigella Sativa Ekstresinin Subaraknoid Kanamaya Bağlı Vasküler Değişiklikler Üzerine Olan Etkisi

Yazar: Mehmet Kürşat KARADAĞ



© Copyright 2026

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş. 'ye aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

Bu kitap "Nigella Sativa Ekstresinin Cas: 490-91-5 Deneysel Subaraknoid Kanamaya Bağlı Vasküler Değişiklikler Üzerine Olan Etkisinin Işık Mikroskopik ve Stereolojik İncelemesi" adlı uzmanlık tezinden üretilmiştir.

ISBN

978-625-362-014-1

Yayın Koordinatörü

Yasin DİLMEN

Kitap Adı

Nigella Sativa Ekstresinin Subaraknoid
Kanamaya Bağlı Vasküler Değişiklikler
Üzerine Olan Etkisi

Sayfa ve Kapak Tasarımı

Akademisyen Dizgi Ünitesi

Yayıncı Sertifika No

47518

Editör

Hakan Hadi KADIOĞLU
ORCID iD: 0000-0002-7744-6241

Baskı ve Cilt

Vadi Matbaacılık

Yazar

Mehmet Kürşat KARADAĞ
ORCID iD: 0000-0001-9123-0597

Bisac Code

MED022000

DOI

10.37609/akya.4149

Kütüphane Kimlik Kartı

Karadağ, Mehmet Kürşat.

Nigella Sativa Ekstresinin Subaraknoid Kanamaya Bağlı Vasküler Değişiklikler Üzerine Olan
Etkisi / Mehmet Kürşat Karadağ, ed. Hakan Hadi Kadioğlu.

Ankara : Akademisyen Yayınevi Kitabevi, 2026.

112 s. ; şekil, tablo. ; 135x210 mm.

Kaynakça var.

ISBN 9786253620141

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A Yenışehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

İÇİNDEKİLER

1. GİRİŞ VE AMAÇ	1
2. GENEL BİLGİLER	5
2.1. Subaraknoid Kanama.....	5
2.1.1. Tanım.....	5
2.1.2. Subaraknoid Kanamanın Tarihçesi.....	5
2.1.3. Epidemiyoloji.....	6
2.1.4. Etyoloji.....	7
2.1.5. Risk Faktörleri	9
2.1.6. Semptom ve Bulgular, Klinik Evrelemeler	10
2.1.6.1. Semptom ve Bulgular	10
2.1.6.2. Klinik Evrelemeler.....	12
2.1.7. Yardımcı Tetkikler.....	14
2.1.8. Anevrizmatik Subaraknoid Kanama'nın Doğal Seyri ve Prognozu.....	17
2.1.9. Anevrizmatik Subaraknoid Kanama'nın Komplikasyonları	18
2.1.10. Ayırıcı Tanı.....	22
2.2. Serebral Vazospazm	22
2.2.1. Tanım, insidans ve zaman aralığı.....	22
2.2.2. Tarihçe	23
2.2.3. Klinik Özellikler	24
2.2.4. Tanı	25
2.2.5. Etyoloji ve Patogenez	26
2.2.5.1. Damar Düz Kaslarında Kasılma.....	27
2.2.5.2. Spazmojenler.....	29
2.2.5.3. İnflamasyon.....	33

2.2.6.	Vazospazmı Önleyici ve Tedavici Edici Yöntemler.....	35
2.2.6.1.	Vazospazmın Farmakolojik Tedavisi	36
2.2.6.2.	Vazospazmın İnvaziv Yöntemlerle Tedavisi...39	
2.3.	Thymoquinone(TQ)	41
2.3.1.	TQ Etki Mekanizması ve Farmakolojik Kullanım Alanları.....	44
3.	GEREÇ ve YÖNTEM	51
3.1.	Deney Grupları	51
3.2.	Cerrahi İşlem.....	52
3.3.	Spesmenlerin İncelenmesi.....	58
4.	BULGULAR	61
4.1.	Histolojik İnceleme.....	61
4.2.	Stereolojik İnceleme.....	68
5.	TARTIŞMA	79
6.	SONUÇ VE ÖNERİLER	87
	KAYNAKLAR.....	89

KAYNAKLAR

1. Weir B. (ed) Subarachnoid Hemorrhage: Causes and cures. Oxford University Press. NY. 1998; 144-176
2. Bederson JBi Connolly ES, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for Healthcare Professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 2009; 40: 994-1025
3. Kocaeli H, Korfalı E. Anevrizmal subaraknoid kanama ve komplikasyonları. Temel Nöroşirurji. Korfalı E, Zileli M (ed). Türk Nöroşirurji Derneği Yayınları, Ankara, 2010, sayfa 803-814
4. Ozdemir M, Bozkurt M, Kahilogullari G, et al. Subaraknoid kanama ve komplikasyonlarının tedavisi. Ankara Üniversitesi Tıp Fakültesi Mecmuası 2011; 64: 52-55
5. De Rooij NK, Linn FH, van der Plas JA, et al. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007 Dec; 78(12): 1365-72.
6. Van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369: 306-18
7. Findlay JM. Cerebral Vasospasm in Youmans' Neurological Surgery, Winn HR(ed), Elsevier, Philedelphia 2014, sayfa 3791-3800
8. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997; 87: 746-51
9. Kırış T, Sencer A. Subaraknoid Kanamanın Komplikasyonları. In: Aksoy K, editor. Temel Nöroşirurji. Ankara: Türk Nöroşirurji Derneği Yayınları, 2005: 448-56
10. Eisenhut M. Vasospasm in cerebral inflammation. Int J Inflam. 2014;2014: 509-707
11. Peterson JW, Kwun BD, Hackett JD et al. The role of inflamattion in experimental vasospasm. J Neurosurg 1990; 72: 767-774
12. Misra HP, Fridovich I. The generation of superoxide radical during the autooxidation of hemoglobin. J Biol Chem 1972; 10: 6960-62
13. Cook DA, Volrath B: Free radicals and intracelluler events associated with cerebrovascular spasm. Cardiovasc Res 1995; 30: 493-500
14. Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella Sativa. Phytother. Res. 2003; 17: 299-305
15. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa seed. Int Immunopharmacol. 2005; 5: 1749-1770
16. Khan MA. Chemical composition and medicinal properties of Nigella Sative Linn, İnflammopharmacology 1999; 7: 15-35

17. Gali-Muhtasib H, El-Najjar N, Schneider-Stock R. The medicinal potential of black seed(*Nigella Sativa*) and its components. *Adv Phytomed* 2006; 2: 133-152
18. Taborsky J, Kunt M, Kloucek P, et al. Identification of potential sources of thymoquinone and related compounds in Asteraceae, Cupressaceae, Lamiaceae, and Ranunculaceae families. *Cent Eur J Chem*. 2012; 10: 1899-1906
19. Mansour MA, Nagi MN, El-Khatib AS, et al. Effects of thymoquinone on antioxidant enzyme activities, lipid peroxidation and DT-diaphorase in different tissues of mice a possible mechanism of action. *Cell Biochem Funct* 2002; 20: 143-151
20. Badary OA, Taha RA, Gamal El-Din AM, et al. Thymoquinone is a potent superoxide anion scavenger. *Drug Chem Toxicol* 2003; 26: 87-98
21. Vaillancourt F, Silva P, Shi Q, et al. Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. *J Cell Biochem*. 2011; 112: 107-117
22. Meurer WJ, Walsh B, Vilke GM, Coyne CJ. Clinical Guidelines for the Emergency Department Evaluation of Subarachnoid Hemorrhage. *J Emerg Med* 2016;50: 696-701.
23. Steiner T, Juvela S, Unterberg A, Jung C, Forsting M, Rinkel G; European Stroke Organization. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. *Cerebrovasc Dis* 2013;35: 93-112.
24. Edlow JA, Malek AM, Ogilvy CS. Aneurysmal subarachnoid hemorrhage: update for emergency physicians. *J Emerg Med* 2008;34: 237- 251
25. Akdemir H: Subaraknoid kanama. Ed: Aksoy K: Temel Nöroşürürji. Türk Nöroşürürji Derneği Yayınları, Ankara 1. Baskı, Cilt 1, 2005; s:441- 448,
26. Frijinc CJ, Kappelle LJ: Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. *Stroke*. 2002; 33: 2115-22
27. Bahar S, Türker K. Subaraknoid kanama. II. Mezuniyet sonrası uygulamalı eğitim kursları. Nöroloji, İstanbul Tıp Fakültesi, 1987:143-159.
28. Biller J, Godersky JC, Adams H. Manangement of Aneurysmal SAH. *Stroke*, 1988; 19: 1300-1305.
29. Ingall TJ, Whisnant JP: Epidemiology of subarachnoid hemorrhage, in Yanagihara T, Piepgras DG, Atkinson JLG (eds): Subarachnoid hemorrhage. New York, Marcel Dekker Inc, 1998; pp: 63-78
30. Binatlı, Ö.A. Uluğ, E. Özhan, İ. Bardakçı, S. ve Özdamar, N. Spontan subaraknoid kanamalar: 273 olguluk retrospektif çalışma, *Türk Serebrovasküler Hastalıklar Dergisi*, 2208; 14, 2, 33-39
31. Gijn, J.V. and Rinkel, J.E. 2001, Subarachnoid haemorrhage: diagnosis, causes and management, *Brain*, 2001; 124: 249-278 p
33. Thompson RA., Pribram HFW., Infantile cerebral aneurysm associated with ophthalmoplegia quadriparesis, *Neurology*,1969; 19:785-789.
34. Vinal PE, Maislin G, Michele JJ, Deitch C, Simeone FA: Seasonal and la-

- titudinal occurrence of cerebral vasospasm and subarachnoid hemorrhage in the northern hemisphere. *Epidemiology* 5 1994; 3: 302-308
35. Chayette D, Chen T L, Bronstein K, Brass L M: Seasonal fluctuation in the incidence of intracranial aneurysm rupture and its relationship to changing climatic conditions. *J Neurosurg*; 1994; 81: 525- 530
 36. Feigin VL, Lawes CM, Bennett DA, et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol*. 2009; 8: 355-69
 37. Grieve JP, Kitchen ND. Aneurysmal Subarachnoid Hemorrhage. Moore AJ, Newell DW. *Neurosurgery Principles and Practice*. Springer. London. 2005; 315-332.
 38. Spears J, Macdonald R, Weir B. Perioperative management of subarachnoid hemorrhage. In: Winn RH, ed., *Youmans Neurological Surgery* 6th ed: Saunders, 2011.
 39. Sandvei MS, Romundstad PR, Muller TB, et al. Risk factors for aneurysmal subarachnoid hemorrhage in a prospective population study: the HUNT study in Norway. *Stroke*. 2009; 40: 1958-62.
 40. Srabia R, Lagares A, Fernandez-Alen JA, et al. Idiopathic subarachnoid hemorrhage: a multicentre series of 220 patients. *Neurocirugia (Astur)*. 2010;21: 441-51.
 41. Etminan N, Beseoglu K, Steiger HJ, et al. The impact of hypertension and nicotine on the size of ruptured intracranial aneurysms. *J Neurol Neurosurg Psychiatry*. 2011;82: 4-7.
 42. Larsson SC, Mannisto S, Virtanen MJ, et al. Dairy foods and risk of stroke. *Epidemiology*. 2009; 20: 355-60.
 43. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. *Neurology*. 2010; 74: 1494-501.
 44. Larsson SC, Mannisto S, Virtanen MJ, et al. Dietary fiber and fiber-rich food intake in relation to risk of stroke in male smokers. *Eur J Clin Nutr*. 2009; 63: 1016-24.
 45. Larsson SC, Mannisto S, Virtanen MJ, et al. Coffee and tea consumption and risk of stroke subtypes in male smokers. *Stroke*. 2008; 39: 1681-7.
 46. Nanda A, Vannemreddy PS, Polin RS, Willis BK. Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators. *Neurosurgery*. 2000;46: 1063-1067
 47. Brown E, Prager J, Lee HY, Ramsey RG. CNS complication of cocaine abuse: prevalence, pathophysiology, and neuroradiology. Review. *AJR* 1992;159: 137-147.
 48. Daras M, Tuchman AJ, Koppel BS, Samkoff LM, Weitzner I, Marc J. et al. Neurovascular complication of cocaine. *Acta Neurol Scand*. 1994;90: 124-129.
 49. Bor AS, Koffijberg H, Wermer MJ, et al. Optimal screening strategy for

- familial intracranial aneurysms: a cost-effectiveness analysis. *Neurology*. 2010; 74: 1671-9.
50. Broderick JP, Brown RD, Jr., Sauerbeck L, et al. Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. *Stroke*. 2009; 40: 1952-7.
 51. Wiebers DO, Whisnant JP, Huston J, 3rd, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. *Lancet*. 2003; 362: 103-10.
 52. Lall RR, Eddleman CS, Bendok BR, et al. Unruptured intracranial aneurysms and the assessment of rupture risk based on anatomical and morphological factors: sifting through the sands of data. *Neurosurg Focus*. 2009; 26: E2.
 53. Dhar S, Tremmel M, Mocco J, et al. Morphology parameters for intracranial aneurysm rupture risk assessment. *Neurosurgery*. 2008; 63: 185-96; discussion 96-7
 54. Lindner SH, Bor AS, Rinkel GJ. Differences in risk factors according to the site of intracranial aneurysms. *J Neurol Neurosurg Psychiatry*. 2010; 81: 116-8.
 55. Burns JD, Huston J, 3rd, Layton KF, et al. Intracranial aneurysm enlargement on serial magnetic resonance angiography: frequency and risk factors. *Stroke*. 2009; 40: 406-11.
 56. Eljovitch L, Higashida RT, Lawton MT, et al. Predictors and outcomes of intraprocedural rupture in patients treated for ruptured intracranial aneurysms: the CARAT study. *Stroke*. 2008; 39: 1501-6.
 57. Butzkueven H, Evans AH, Pitman A, et al. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. *Neurology*. 2000; 55: 1315-20.
 58. Brilstra EH, Rinkel GJ, Algra A, et al. Rebleeding, secondary ischemia, and timing of operation in patients with subarachnoid hemorrhage. *Neurology*. 2000; 55: 1656-60.
 59. Connolly ES, Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2012; 43: 1711-37.
 60. McDonald RL, Weir B: Perioperative Management of Subarachnoid Hemorrhage. Youmans Fifth edition, Vol II, Philadelphia, Elsevier 1996; 1813-38.
 61. Takahashi M, Macdonald RL. Subarachnoid Hemorrhage. *Contemporary Neurosurgery*. 2006; 28: 1-8.
 62. McCarron MO, Alberts MJ, McCarron P. A systematic review of Terson's syndrome: frequency and prognosis after subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry*. 2004; 75: 491-3.
 63. Stiebel-Kalish H, Turtel LS, Kupersmith MJ. The natural history of nontra-

- umatic subarachnoid hemorrhage-related intraocular hemorrhages. *Retina*. 2004; 24: 36-40.
64. Khechinashvili G, Asplund K. Electrocardiographic changes in patients with acute stroke: a systematic review. *Cerebrovasc Dis*. 2002; 14: 67-76.
 65. Toussaint LG, 3rd, Friedman JA, Wijdicks EF, et al. Survival of cardiac arrest after aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 2005; 57: 25-31; discussion 25-31
 66. Kocaeli H, Korfali E: Subaraknoid kanama: Anevrizmalar. *Nörobilimde Bugün* 2003;1: 1-6.
 67. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. *Neurosurgery*. 1980; 6: 1-9.
 68. Edlow J A: Diagnosis of subarachnoid hemorrhage, *Neurocrit. Care*. 2005; 2(2); 99- 109.
 69. Boesiger BM, Shiber JR. Subarachnoid hemorrhage diagnosis by computed tomography and lumbar puncture: are fifth generation CT scanners better at identifying subarachnoid hemorrhage? *J Emerg Med*. 2005; 29: 23-7.
 70. Nagai M, Watanabe E. Benefits of clipping surgery based on three-dimensional computed tomography angiography. *Neurol Med Chir (Tokyo)*. 2010; 50: 630-7.
 71. Uysal E, Yanbuluğlu B, Ertürk M, Kılınç M.B, Başak M. Akut subaraknoid kanamalı olgularda serebral anevrizma tanısında spiral BT anjiyografi. *Diagn Interv Radiol* 2005; 11: 77-82
 72. Fiebach JB, Schellinger PD, Gass A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. *Stroke*. 2004; 35: 502-6.
 73. Mitchell P, Wilkinson ID, Hoggard N, et al. Detection of subarachnoid haemorrhage with magnetic resonance imaging. *J Neurol Neurosurg Psychiatry*. 2001; 70: 205-11
 74. Linn FH, Voorbij HA, Rinkel GJ, et al. Visual inspection versus spectrophotometry in detecting bilirubin in cerebrospinal fluid. *J Neurol Neurosurg Psychiatry*. 2005; 76: 1452-4.
 75. Duff GP. Lumbar puncture in spontaneous Subarachnoid hemorrhage. *Neurosurg Psychiatry* 1990; 53: 365-72.
 76. Beetham R, group UNflW. Recommendations for CSF analysis in subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry*. 2004; 75: 528
 77. O'Neill J, McLaggan S, Gibson R. Acute headache and subarachnoid haemorrhage: a retrospective review of CT and lumbar puncture findings. *Scott Med J*. 2005; 50: 151-3.
 78. Van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. *Lancet*. 2007; 369: 306-18.
 79. Van Rooij WJ, Peluso JP, Sluzewski M, et al. Additional value of 3D rotational angiography in angiographically negative aneurysmal subarachnoid

- hemorrhage: how negative is negative? *AJNR Am J Neuroradiol.* 2008; 29: 962-6.
80. Struffert T, Eyupoglu IY, Huttner HB, et al. Clinical evaluation of flat-panel detector compared with multislice computed tomography in 65 patients with acute intracranial hemorrhage: initial results. *Clinical article. J Neurosurg.* 2010; 113: 901-7.
 81. Doelken M, Struffert T, Richter G, et al. Flat-panel detector volumetric CT for visualization of subarachnoid hemorrhage and ventricles: preliminary results compared to conventional CT. *Neuroradiology.* 2008; 50: 517-23.
 82. Gelfand AA, Josephson SA. Substantial radiation exposure for patients with subarachnoid hemorrhage. *J Stroke Cerebrovasc Dis.* 2011; 20: 131-3.
 83. Mamourian AC, Young H, Stiefel MF. Cumulative radiation dose in patients admitted with subarachnoid hemorrhage: a prospective study using a self-developing film badge. *AJNR Am J Neuroradiol.* 2010; 31: 1787-90.
 84. Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. *Lancet Neurol.* 2009; 8: 635-42.
 85. Weir B, Macdonald RL. Intracraial aneurysms and subarachnoid hemorrhage. An overview. In: Wilkins RH, Rengechary SS, editors. *Neurosurgery.* NewYork: McGraw Hill, 1996: 2191-2214
 86. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. *Stroke* 1997; 28: 660-64.
 87. Ayala C, Greenlund KJ, Croft JB, et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995-1998. *Am J Epidemiol.* 2001; 154: 1057-63
 88. Britz GW, Winn HR. The natural history of cerebral aneurysms. In: Winn RH, ed., *Youmans Neurological Surgery.* 6th ed: Saunders, 2011.
 89. Samra SK, Giordani B, Caveney AF, et al. Recovery of cognitive function after surgery for aneurysmal subarachnoid hemorrhage. *Stroke.* 2007; 38: 1864-72.
 90. Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. *Stroke.* 2010; 41: e519-36.
 91. Wermer MJ, Kool H, Albrecht KW, et al. Subarachnoid hemorrhage treated with clipping: long-term effects on employment, relationships, personality, and mood. *Neurosurgery.* 2007; 60: 91-7; discussion 97-8.
 92. Rabinstein AA, Weigand S, Atkinson JL, et al. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. *Stroke.* 2005; 36: 992-7
 93. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. *Crit Care Med.* 2006; 34: 617-23; quiz 24.
 94. Pierot L, Cognard C, Anxionnat R, et al. Ruptured intracranial aneurysms:

- factors affecting the rate and outcome of endovascular treatment complications in a series of 782 patients (CLARITY study). *Radiology*. 2010; 256: 916-23
95. Berman MF, Solomon RA, Mayer SA, et al. Impact of hospital-related factors on outcome after treatment of cerebral aneurysms. *Stroke*. 2003; 34: 2200-7.
 96. Hillman J, Fridriksson S, Nilsson O, et al. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study. *J Neurosurg*. 2002; 97: 771-8.
 97. Naidech AM, Janjua N, Kreiter KT, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. *Arch Neurol*. 2005; 62: 410-6.
 98. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. *Stroke*. 2001; 32: 1176-80.
 99. Tanno Y, Homma M, Oinuma M, et al. Rebleeding from ruptured intracranial aneurysms in North Eastern Province of Japan. A cooperative study. *J Neurol Sci*. 2007; 258: 11-6.
 100. Cha KC, Kim JH, Kang HI, et al. Aneurysmal rebleeding: factors associated with clinical outcome in the rebleeding patients. *J Korean Neurosurg Soc*. 2010; 47: 119-23.
 101. Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP. The International Cooperative Study on the Timing of Aneurysms Surgery. Part 2: surgical results. *J Neurosurg* 1990;73: 37-475
 102. Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. *Stroke*. 2010; 41: 2391-5
 103. Komotar RJ, Hahn DK, Kim GH, et al. Efficacy of lamina terminalis fenestration in reducing shunt-dependent hydrocephalus following aneurysmal subarachnoid hemorrhage: a systematic review. *Clinical article. J Neurosurg*. 2009; 111: 147-54.
 104. Little AS, Zabramski JM, Peterson M, et al. Ventriculoperitoneal shunting after aneurysmal subarachnoid hemorrhage: analysis of the indications, complications, and outcome with a focus on patients with borderline ventriculomegaly. *Neurosurgery*. 2008; 62: 618-27; discussion 18-27
 105. Kwon J, Sung S, Song Y, Choi H, Huh J, Kim H. Predisposing Factors Related to Shunt-Dependent Chronic Hydrocephalus after Aneurysmal Subarachnoid Hemorrhage. *J Korean Neurosurg Soc*. 2008; 43: 177-181
 106. Levy EI, Scarrow AM, Firlik AD, Kanal E, Rubin G, Kirby L, Yonas H. Development of obstructive hydrocephalus with lumboperitoneal shunt following subarachnoid hemorrhage. *Clinical Neurology and Neurosurgery*. 1999;101: 79-85.

107. Mura J, Rojas-Zalazar D, Ruiz A, et al. Improved outcome in high-grade aneurysmal subarachnoid hemorrhage by enhancement of endogenous clearance of cisternal blood clots: a prospective study that demonstrates the role of lamina terminalis fenestration combined with modern microsurgical cisternal blood evacuation. *Minim Invasive Neurosurg.* 2007; 50: 355-62
108. Hellingman CA, van den Bergh WM, Beijer IS, et al. Risk of rebleeding after treatment of acute hydrocephalus in patients with aneurysmal subarachnoid hemorrhage. *Stroke.* 2007; 38: 96-9.
109. Platz J, Guresir E, Wagner M, et al. Increased risk of delayed cerebral ischemia in subarachnoid hemorrhage patients with additional intracerebral hematoma. *J Neurosurg.* 2016: 1-7
110. Choi KS, Chun HJ, Yi HJ, et al. Seizures and Epilepsy following Aneurysmal Subarachnoid Hemorrhage: Incidence and Risk Factors. *J Korean Neurosurg Soc.* 2009; 46: 93-8.
111. Lin CL, Dumont AS, Lieu AS, et al. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. *J Neurosurg.* 2003; 99: 978-85.
112. Cabral NL, Goncalves AR, Longo AL, et al. Incidence of stroke subtypes, prognosis and prevalence of risk factors in Joinville, Brazil: a 2 year community based study. *J Neurol Neurosurg Psychiatry.* 2009; 80: 755-61.
113. Rosengart AJ, Huo JD, Tolentino J, et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. *J Neurosurg.* 2007; 107: 253-60.
114. Chandy D, Sy R, Aronow WS, et al. Hyponatremia and cerebrovascular spasm in aneurysmal subarachnoid hemorrhage. *Neurol India.* 2006; 54: 273-5.
115. Nakagawa I, Kurokawa S, Takayama K, et al. [Increased urinary sodium excretion in the early phase of aneurysmal subarachnoid hemorrhage as a predictor of cerebral salt wasting syndrome]. *Brain Nerve.* 2009; 61: 1419-23.
116. Rahman M, Friedman WA. Hyponatremia in neurosurgical patients: clinical guidelines development. *Neurosurgery.* 2009; 65: 925-35; discussion 35-6.
117. Sayama T, Inamura T, Matsushima T, et al. High incidence of hyponatremia in patients with ruptured anterior communicating artery aneurysms. *Neurol Res.* 2000; 22: 151-5.
118. Kilpatrick MM, Lowry DW, Firlik AD, et al. Hyperthermia in the neurosurgical intensive care unit. *Neurosurgery.* 2000; 47: 850-5; discussion 55-6
119. Dorhout Mees SM, Luitse MJ, van den Bergh WM, et al. Fever after aneurysmal subarachnoid hemorrhage: relation with extent of hydrocephalus and amount of extravasated blood. *Stroke.* 2008; 39: 2141-3.
120. Rabinstein AA, Sandhu K. Non-infectious fever in the neurological inten-

- sive care unit: incidence, causes and predictors. *J Neurol Neurosurg Psychiatry*. 2007; 78: 1278-80.
121. Fernandez A, Schmidt JM, Claassen J, et al. Fever after subarachnoid hemorrhage: risk factors and impact on outcome. *Neurology*. 2007; 68: 1013-9.
 122. Zhang G, Zhang JH, Qin X. Fever increased in-hospital mortality after subarachnoid hemorrhage. *Acta Neurochir Suppl*. 2011; 110: 239-43.
 123. Ray WZ, Strom RG, Blackburn SL, et al. Incidence of deep venous thrombosis after subarachnoid hemorrhage. *J Neurosurg*. 2009; 110: 1010-4.
 124. Dalbastı T. Serebral vazospazm sağaltımı. In: Kumral E, ed., *Santral Sinir Sisteminin Damarsal Hastalıkları: Güneş Tıp Kitabevleri*, 2011
 125. Hackett ML, Anderson CS. Health outcomes 1 year after subarachnoid hemorrhage: An international population-based study. The Australian Cooperative Research on Subarachnoid Hemorrhage Study Group. *Neurology*. 2000; 55: 658-62
 126. Mayer SA, Kreiter KT, Copeland D, et al. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. *Neurology*. 2002; 59: 1750-8.
 127. Powell J, Kitchen N, Heslin J, et al. Psychosocial outcomes at 18 months after good neurological recovery from aneurysmal subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry*. 2004; 75: 1119-24
 128. Aoyama K, Fushimi Y, Okada T, Miyasaki A, Taki H, Shibamoto K, Togashi K. Detection of Symptomatic vasospasm after subarachnoid hemorrhage: initial findings from single time-point and serial measurements with arterial spin labelling. *Eur Radiol*. 2012
 129. Ishikawa M, Kusaka G, Yamaguchi N, Sekizuka E, Nakadate H, Minamitani H, Shinoda S, Watanabe E. Platelet and Leukocyte Adhesion in the Microvasculature at the Cerebral Surface Immediately after Subarachnoid Hemorrhage. *Neurosurgery*. 2009;64: 546-554.
 130. Kim GH, Kellner CP, Hickman ZL, Zacharia BE, Starke RM, Hwang BY, Ducruet AF, Fernandez L, Mayer SA, Tracey KJ, Connolly ES. A Phase I Clinical Trial of Tiopronin, A Putative Neuroprotective Agent, in Aneurysmal Subarachnoid Hemorrhage. *Neurosurgery*. 2010; 67: 182-186.
 131. Schuiling WJ, de Weerd AW, Dennesen PJ, et al. The simplified acute physiology score to predict outcome in patients with subarachnoid hemorrhage. *Neurosurgery*. 2005; 57: 230-6; discussion 30-6.
 132. Findlay JM: *Cerebral vasospasm in Youmans' Neurological Surgery*, Winn HR (ed), Elsevier, Philadelphia 2014; sayfa: 3791-3800
 133. Cook, A.D. Mechanisms of cerebral vasospasm in subarachnoid haemorrhage, *Pharmac Ther*, 1995; 66: 259-284 p.
 134. Mayberg M: Cerebral Vasospasm, *Neurosurg Clin N Am* 1998;9: 615-627
 135. Sen O, Caner H, Aydin MV, Ozen O, Atalay B, Altınors N, Bavbek M. The effect of mexiletine on the level of lipid peroxidation and apoptosis of en-

- dothelium following experimental subarachnoid hemorrhage. *Neurol Res.* 2006;28(8):859-63.
136. Le Roux PD, Winn HR. Surgical decision making for the treatment of cerebral aneurysms. In; Winn HR, editor. *Youmans Neurological Surgery.* Philadelphia Saunders 2003; 1793-812
 137. Haley EC Jr, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM: A randomized, double blind, vehicle controlled trial of tirilazad mesylate in patients with aneurismal subarachnoid hemorrhage: A cooperative study in North America. *J neurosurg* 1997;86: 467-474
 138. Gurdjian T, Thomas LM. Verebral vasospasm in Jinken PJ. Brsyn GV (eds): *Handbook of Clinical Neurology, Vol 12.* Amsterdam: North Holland Pub Co, 1975; 511.
 139. Ecker A, Reimenschneider PA. Arteriographic demonstration of spazm of the intracranial arteries with special references to saccular aneurysms. *J Neurosurgery.* 1951;8: 660-667.
 140. Giannotta SL, McGillicuddy JE, Kint GW. Diagnosis and treatment of cerebral vasospasm. *Surg Neurol.* 1977; 8: 286-290.
 141. Grubb RL Jr, Raichle ME, Eichling JO, Gado MH: Effects of subarachnoid hemorrhage on cerebral blood volume, blood flow and oxygen utilization in humans. *J Neurosurg* 1977; 46 (4): 446-453
 142. Niizuma H, Kwak R, Otabe K, Suzuki J. Angiography study of cerebral vasospasm following the rupture of intracranial aneurysms: Part II. Relation between the site of aneurysm and the occurrence of the vasospasm. *Surg Neurol.* 1979;2: 263-267.
 143. Sasaki T, Wakai S, Asano T, Watanabe T, Kirino T, Şano K. The effect of a lipid hydroperoxide of arachidonic acid on the canine basilar artery. An experimental study on cerebral vasospasm. *J Neurosurgery.* 1981;54: 357-365.
 144. Zubkov YN, Nikiforov BM, Shustin VA: Balloon catheter technique for dilatation of constricted cerebral arteries after aneurysmal SAH. *Acta Neurochir (Wien)* 1984; 70: 65-79, 1984.
 145. Rinkel GS, Wijdicks EF, Vermulan M, Hasan D, Brouwes PJ, van Gijn J. The clinical course of perimesencephalic non aneurysmal subarachnoid hemorrhage. *Ann Neurol* 1991; 29: 463-8.
 146. Barker FG, Heros RC: Clinical aspects of vasospasm. *Neurosurgery Clinics of North America* 1990; 1,2:277-287
 147. Mills JN, Mehta V, Russin J, et al. Advanced imaging modalities in the detection of cerebral vasospasm. *Neurol Res Int.* 2013;2013:415960.
 148. Aaslid R, Huber P, Nornes H: Evaluation of cerebrovasculospasm with transcranial Doppler ultrasound. *J Neurosurg* 1984;60: 37-41.
 149. Carlson AP, Yonas H. Radiographic assesment of vasospasm after aneurysmal subarachnoid hemorrhage: the physiological perspective. *Neurol Res.* 2009; 31: 593-604.
 150. Yonas H: Cerebral blood measurements in vasospasm. *Neurosurg Clin*

- North Am 1990; 1: 307-318
151. Claassen J, Hirsch LJ, Kreiter KT, et al. Quantitative continuous EEG for detecting delayed cerebral ischemia in patients with poor-grade subarachnoid hemorrhage. *Clin Neurophysiol.* 2004; 115: 2699-710.
 152. Heran NS, Hentschel SJ, Toyota BD. Jugular bulb oximetry for prediction of vasospasm following subarachnoid hemorrhage. *Can J Neurol Sci.* 2004; 31: 80-6.
 153. Dietrich HH, Dacey RG, Jr. Molecular keys to the problems of cerebral vasospasm. *Neurosurgery.* 2000; 46: 517-30.
 154. Tani E. Molecular mechanisms involved in development of cerebral vasospasm. *Neurosurg Focus.* 2002; 12:ECP1
 155. Reilly C, Amidei C, Tolentino J, et al. Clot volume and clearance rate as independent predictors of vasospasm after aneurysmal subarachnoid hemorrhage. *J Neurosurg.* 2004; 101: 255-61
 156. Heistad DD, Kontos HA: Cerebral circulation, in Shepherd JT, Abboud FM(eds): *Handbook of Physiology. Section: Circulation.* Bethesda, Am Physiol Soc, 1993, vol 3, pp 137-182.
 157. Aihara Y, Jahromi BS, Yassari R, Nikitina E, Agbaje-Williams M, Macdonald RL. Molecular profile of vascular ion channels after experimental subarachnoid hemorrhage. *J Cereb Blood Flow Metab.* 24 2004; 1: 75-83
 158. Kitazono T, Faraci FM, Taguchi H, Heistad DD: Role of potassium channels in cerebral blood vessels. *Stroke* 26 1995; 9: 1713-1723
 159. Winder SJ, Allen BG, Clément-Chomienne O, Walsh MP: Regulation of smooth muscle actin-myosin interaction and force by calponin. *Acta Physiol Scand* 1998; 164: 415-426
 160. Nelson MT, Patlak JB, Worley JF, Standen NB: Calcium channels, potassium channels, voltage dependence of arterial smooth muscle tone. *Am J Physiol* 259 1990; 1: C3-18
 161. Zuccarello M, Bonasso CL, Sperelakis N: Role of membrane potential in vasospasm after SAH, in Findlay JM(ed): *Cerebral Vasospasm.* Amsterdam, Els Sci Pub Co, 1993; pp 229-233
 162. Zhang H, Cook D: Cerebral vascular smooth muscle potassium channels and their possible role in the management of vasospasm. *Pharmacol Toxicol* 1994; 75:327-336
 163. Macdonald RL: Pathophysiology and molecular genetics of vasospasm. *Acta Neurochir Suppl (Wien)* 2001;77: 7-11
 164. Kwan AL, Solenski NJ, Kassell NF, Lee KS: Inhibition of nitric oxide generation and lipid peroxidation attenuates hemolysate-induced injury to cerebrovascular endothelium. *Acta Neurochir (Wien)* 1997; 139:240-248
 165. Steele JA, Stockbridge N, Maljkovic G, Weir B: Free radicals mediate actions of oxyhemoglobin on cerebrovascular smooth muscle cells. *Circ Res* 1991; 68:416-423.
 166. Grasso G: An overview of new pharmacological treatments for cerebrovas-

- cular dysfunction after experimental subarachnoid hemorrhage. *Brain Res Brain Res Rev* 2004; 44 : 49-63
167. Ignarro LJ: Biosynthesis and metabolism of endothelium-derived nitric oxide. *Annu Rev Pharmacol Toxicol* 1990; 30: 535-560.
168. Zabramski JM, Spetzler RF, Bonstelle C. Chronic cerebral vasospasm: effect of volume and timing of hemorrhage in a canine model. *Neurosurgery*. 1986; 18: 1-6.
169. Zhang ZD, Yamini B, Komuro T, et al. Vasospasm in monkeys resolves because of loss of and encasement of subarachnoid blood clot. *Stroke*. 2001; 32: 1868-74
170. Nishizawa S, Laher I. Signaling mechanisms in cerebral vasospasm. *Trends Cardiovasc Med*. 2005; 15: 24-34
171. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. *Pharmacol Ther*. 2005; 105: 23-56.
172. Clark JF, Sharp FR. Bilirubin oxidation products (BOXes) and their role in cerebral vasospasm after subarachnoid hemorrhage. *J Cereb Blood Flow Metab*. 2006; 26: 1223-33.
173. Koliass AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. *J Neurosci Res*. 2009; 87: 1-11.
174. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. *Am J Clin Nutr*. 1993; 57: 715S-25S,
175. Peiro C, Angulo J, Rodriguez-Manas L, Llergo JL, Vallejo S, Cercas E, Sanchez-Ferrer CF. Vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin. *Br J Pharmacol*. 1998; 125: 637-44
176. Akyol Ö, İsci N, Temel İ, et al. The relationship between plasma and erythrocyte antioxidant enzymes and lipid peroxidation in patients with rheumatoid arthritis. *Joint Bone Spine* 2001; 68:31 1-7
177. Tamer L, Polat G, Eskandari G, Ercan B, Atik U. Serbest radikaller. *Mersin Üniv Tıp Fak Der*, 2000; 1: 52-58.
178. Hanggi D, Steiger HJ. Nitric oxide in subarachnoid haemorrhage and its therapeutic implications. *Acta Neurochir (Wien)*. 2006; 148: 605-13; discussion 13
179. Pluta RM, Afshar JK, Boock RJ, Oldfield EH: Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. *J Neurosurg* 1998; 88:557-561
180. Gibson QH, Roughton FJW: The kinetics and equilibria of the reactions of nitric oxide with sheep haemoglobin. *J Physiol (Lond)* 1957; 136:507-526
181. R. Pluta and B. Thompson et al., Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. *J Neurosurg* 1996; 84: 648-654, 1996.
182. A. Wennmalm and G. Bentin et al., Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. *Br J Pharmacol* 1992; 106: 507-508

183. Yanagisawa M, Kurihara H, Kimura S, et al. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca²⁺ channels. *J Hypertens Suppl.* 1988; 6: S188-91.
184. Kessler IM, Pacheco YG, Lozzi SP, et al. Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. *Surg Neurol.* 2005; 64 Suppl 1: S1:2-5; discussion S1:5.
185. Chow M, Dumont AS, Kassell NF. Endothelin receptor antagonists and cerebral vasospasm: an update. *Neurosurgery.* 2002; 51: 1333-41; discussion 42.
186. Siasios, I., Kapsalaki, E.Z. and Fountas, K.N., 2013, Cerebral vasospasm Pharmacological treatment: An update, *Neurology Research International* 1, doi:10.1155 2013; 571328
187. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature* 1988;332:411-5.
188. Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. *Jpn J Pharmacol.* 2002; 88: 227-49.
189. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. *Physiol Rev.* 2002; 82: 131-85.
190. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. *Neurosurgery.* 2003; 53: 123-33; discussion 33-5.
191. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. *J Neurol Neurosurg Psychiatry.* 2001; 70: 534-7
192. Bowman G, Bonneau RH, Chinchilli VM, Tracey KJ, Cockcroft KM. A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. *Neurocrit Care.* 2006; 5: 222-9
193. Gallia GL, Tamargo RJ. Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage. *Neurol Res.* 2006; 28: 750-8
194. Zhou ML, Shi JX, Hang CH, Cheng HL, Qi XP, Mao L, Chen KF, Yin HX. Potential contribution of nuclear factor-kappa B to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. *J Cereb Blood Flow Metab.* Feb 7 2007.
195. Nam DH, Kim JS, Hong SC, Lee WH, Lee JI, Shin HJ, Park K, Eoh W, Han DH, Kim JH. Expression of interleukin-1 beta in lipopolysaccharide stimulated monocytes derived from patients with aneurysmal subarachnoid hemorrhage is correlated with cerebral vasospasm. *Neurosci Lett.* 2001; 312: 41-4
196. Peterson JW, Kwun BD, Hackett JD, Zervas NT. The role of inflammation in experimental cerebral vasospasm. *J Neurosurg.* 1990; 72: 767-74
197. Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF

- in patients with vasospasm following aneurysmal SAH. *Neuro Endocrinol Lett.* 2004; 25: 141-7
198. Borel CO, McKee A, Parra A, et al. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. *Stroke.* 2003; 34: 427-33.
 199. Zubkov AY, Ogihara K, Bernanke DH, et al. Apoptosis of endothelial cells in vessels affected by cerebral vasospasm. *Surg Neurol.* 2000; 53: 260-6.
 200. Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. *Arch Neurol.* 2001; 58: 1209-12.
 201. Kammersgaard LP, Jorgensen HS, Rungby JA, et al. Admission body temperature predicts long-term mortality after acute stroke: the Copenhagen Stroke Study. *Stroke.* 2002; 33: 1759-62.
 202. Weir B, Macdonald RL, Stoodley M: Etiology of vasospasm. *Acta Neurochir Suppl (Wien)* 1999; 72: 27-46.
 203. Sen J, Belli A, Albon H, Morgan L, Petzold A, Kitchen N. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. *Lancet Neurol.* 2003; 2: 614- 621
 204. Kassell NF, Helm G, Simmons N, Phillips CD, Cail WS. Treatment of cerebral vasospasm with intraarterial papaverine. *J Neurosurg* 1992; 77: 848-52
 205. Feigin VL, Rinkel GJ, Algra A, et al. Circulatory volume expansion for aneurysmal subarachnoid hemorrhage. *Cochrane Database Syst Rev.* 2000: CD000483.
 206. Dankbaar JW, Slooter AJ, Rinkel GJ, et al. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. *Crit Care.* 2010;14:R23.
 207. Treggiari MM, Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H. Hemodynamic management of subarachnoid hemorrhage. *Neurocrit Care.* 2011; 15: 329-35
 208. Komotar RJ, Schmidt JM, et al. Resuscitation and critical care of poor-grade subarachnoid hemorrhage. *Neurosurgery.* 2009; 64: 397-410
 209. Qizilbash N, Lewington SL, Lopez-Arrieta JM. Corticosteroids for acute ischaemic stroke. *Cochrane Database Syst Rev.* 2000: CD000064.
 210. Lannes M, Teitelbaum J, del Pilar Cortes M, et al. Milrinone and hemoostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital Protocol. *Neurocrit Care.* 2012;16: 354-62
 211. Huang D, Shenoy A, Cui J, et al. In situ detection of AP sites and DNA strand breaks bearing 3'-phosphate termini in ischemic mouse brain. *FASEB J.* 2000; 14: 407-17.
 212. Bardi P, Urso R, De Lalla A, et al. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. *Clin*

- Pharmacol Ther. 2002; 72: 556-61.
213. Roos YB, Levi M, Carroll TA, et al. Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage. *Stroke*. 2001; 32: 1860-2.
 214. Zhao J, Zhou D, Guo J, et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. *Neurol Med Chir (Tokyo)*. 2011; 51: 679-83.
 215. Linfante I, Delgado-Mederos R, Andreone V, et al. Angiographic and hemodynamic effect of high concentration of intra-arterial nicardipine in cerebral vasospasm. *Neurosurgery*. 2008;63: 1080-6; discussion 86-7.
 216. Van den Bergh WM, Algra A, van der Sprenkel JW, et al. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 2003; 52: 276-81; discussion 81-2.
 217. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. *J Neurosurg*. 2005; 103: 9-17.
 218. Bautista C. Unresolved issues in the management of aneurysmal subarachnoid hemorrhage. *AACN Adv Crit Care*. 2012; 23: 175-85.
 219. McGirt MJ, Blessing R, Alexander MJ, et al. Risk of cerebral vasospasm after subarachnoid hemorrhage reduced by statin therapy: A multivariate analysis of an institutional experience. *J Neurosurg*. 2006; 105: 671-4.
 220. Veldeman M, Hollig A, Clusmann H, et al. Delayed cerebral ischaemia prevention and treatment after aneurysmal subarachnoid haemorrhage: a systematic review. *Br J Anaesth*. 2016; 117: 17-40.
 221. Hamada J, Kai Y, Morioka M, et al. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cisterna magna: a prospective randomized study. *Stroke*. 2003; 34: 2549-54.
 222. Aydin HE, Ozbek Z, Aydin N, et al. Application of lumbar drainage in vasospasm after spontaneous subarachnoid hemorrhage and prevention of late cerebral infarction. *Acta Neurochir Suppl*. 2015; 120: 255-8.
 223. Dalbasti T, Karabiyikoglu M, Ozdamar N, et al. Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. *J Neurosurg*. 2001; 95: 44-50.
 224. Darby JM, Yonas H, Marks EC, et al. Acute cerebral blood flow response to dopamine-induced hypertension after subarachnoid hemorrhage. *J Neurosurg*. 1994;80: 857-64.
 225. Findlay JM. Cerebral vasospasm. In: Winn HR, ed., *Youmans Neurological Surgery*. 6th ed: Saunders, 2011.
 226. Velat GJ, Kimball MM, Mocco JD, et al. Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-a-

- analyses in the literature. *World Neurosurg.* 2011; 76: 446-54
227. Inamasu J, Nakamura Y, Saito R et al. Endovasküler treatment for poor-grade subaraknoid hemorrhage in the acute stage: Has the outcome been improved. *Neurosurgery* 50: 1199-1206,202
228. Darakhshan S, Pour AB, Colagar AH, Sisakhtnezhad S, et al. Thyymoquinone and its therapeutic potentials. *Pharmacological Research.* 2015; 95-96: 138-158.
229. Al-Shabana OA, Badry OA, Nagi MN, Al-Gharably NM, Al-Rikabi AC, Al-Bekairi AM. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its anti-tumor activity. *J Exp Clin Cancer Res* 1998;17: 193– 8.
230. Daba M.H, Abdel-Rahman M.S. et al. Hepatoprotective activity of thymoquinone in isolated rat hepatocytes *Toxicol. Lett.* 1998; 95: 23-29
231. Houghton PJ, Zarka R, Heras B, Hoult JRS et al. Fixed oil of *Nigella Sativa* and derived Thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. *Plnata Med.* 1995;61: 33-36
232. Mansour M, Tornhamre S. Inhibition of 5-lipoxygenase and leukotriene C4 synthase in human blood cells by thymoquinone. *J Enzyme Med Chem,* 2004; 19: 431-6
233. Gürdöl F, Ademoğlu E. *Biyokimya. Nobel Tıp Kitabevi, İstanbul.* 1. Baskı, 2006.
234. El-Dakhakhny M, Madi NJ, Lembert N, Ammon HP. *Nigella sativa* oil, nigellone and derived thymoquinone inhibit synthesis of 5-lipoxygenase products in polymorphonuclear leukocytes from rats. *J Ethnopharmacol* 2002;81: 161–164
235. M. Khader, P.M. Eckl, N. Bresgen Effects of aqueous extracts of medicinal plants on MNGG-treated rat hepatocytes in primary cultures *J. Ethnopharmacol.* 2007;112: 199-202
236. H. JrahHarzallah, S. BenHadjKhalifa, W.Y. Almawi, A. Maaloul, Z. Houas, T. Mahjoub Effect of thymoquinone on 1,2-dimethyl-hydrazine-induced oxidative stress during initiation and promotion of colon carcinogenesis *Eur. J. Cancer,* 2013; 49: 127-1135
237. M. Lang, M. Borgmann, G. Oberhuber, R. Evstatiev, K. Jimenez, K.W. Dammann Thymoquinone attenuates tumor growth in *ApcMin* mice by interference with Wnt-signaling *Mol. Cancer,* 2013; 12: 41
238. R.L. Gurung, S.N. Lim, A.K. Khaw, J.F. Soon, K. Shenoy, S. Mohamed Ali, et al. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells 2010; 5: 12124
239. K. Kolli-Bouhafs, A. Boukhari, A. Abusnina, E. Velot, J.P. Gies, C. Lugnier, et al. Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation *Investig. New Drugs,* 2012; 30: 2121-2131
240. R. VelhoPereira, A. Kumar, B.N. Pandey, A.G. Jagtap, K.P. Mishra *Radiosen-*

- sitization in human breast carcinoma cells by thymoquinone: role of cell cycle and apoptosis *Cell Biol. Int.* 2011; 35: 1025-1029
- 241.O.A. Badary, O.A. Al-Shabanah, M.N. Nagi, A.C. Al-Rikabi, M.M. ElmarzarInhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone *Eur. J. Cancer Prev.*1999;8: 435-440
- 242.S. Banerjee, A.O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, etal. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer *Cancer Res.*2009;69: 5575-5583
- 243.H.U. GaliMuhtasib, W.G. AbouKheir, L.A. Kheir, N. Darwiche, P.A. CrooksMolecular pathway for thymoquinone-induced cell cycle arrest and apoptosis in neoplastic keratinocytes *Anticancer Drugs*, 2004;15: 389-399
- 244.S.H. Jafri, J. Glass, R. Shi, S. Zhang, M. Prince, H. Kleiner-HancockThymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo *J. Exp. Clin. Cancer Res.*2010; 29: 87
- 245.Bromberg JE, Rinkel GJ, Algra A, Greebe P, vanDuyn CM, Hasan D, Limburg M, ter Berg H.W, Wijdicks EF, vanGijn J: Subarachnoid haemorrhage in first and second degree relatives of patients with subarachnoid haemorrhage. *BMJ* 1995; 311: 288-289.
- 246.M. Hamdy, R.A. TahaEffects of *Nigella sativa* oil and thymoquinone on oxidative stress and neuropathy in streptozotocin-induced diabetic rats *Pharmacology*, 2009;84: 127-134
- 247.A.O. AbdelZaher, M.G. Mostafa, H.M. Farghly, M.M. Hamdy, G.A. Omran, N.K. Al-ShaibaniInhibition of brain oxidative stress and inducible nitric oxide synthase expression by thymoquinone attenuates the development of morphine tolerance and dependence in mice *Eur. J. Pharmacol.* 2013; 702: 62-70
- 248.K. Radad, K. Hassanein, M. Al-Shraim, R. Moldzio, W.D. RauschThymoquinone ameliorates lead-induced brain damage in Sprague Dawley rats *Exp. Toxicol. Pathol.*2014;66: 13-17
- 249.El-Mahmoudy A, Matsuyama H, Borgan M A, Shimizua Y, El-Sayed MG, Minamotob N, Takewakia T. Thymoquinone suppresses expression of inducible nitric oxide synthase in rat macrophages. *International Immunopharmacology*, 2002; 2: 1603-1611.
- 250.A.H. Alhebshi, M. Gotoh, I. SuzukiThymoquinone protects cultured rat primary neurons against amyloid β -induced neurotoxicity *Biochem. Biophys. Res. Commun.*2013;433:362-367
- 251.F. Celik, C. Göçmez, H. Karaman, K. Kamaşak, I. Kaplan, E. Akıl, et al. Therapeutic effects of thymoquinone in a model of neuropathic pain *Curr. Ther. Res. Clin. Exp.*2014;76: 11-16
- 252.El Gazzar M, El Mezayen R, Nicolls MR, Marecki JC, Dreskin SC. Down regulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma. *Biochimica et Biophysica Acta*, 2006; 1760: 1088-1095

253. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schutt S Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. *J Neurol Neurosurg Psychiatry*. 2001; 70(4): 534-7.
254. Mahgoub AA. Thymoquinone protects against experimental colitis in rats. *Toxicol Lett* 2003;143:133- 43.
255. M.A. Khan, M.K. Ashfaq, H.S. Zuberi, M.S. Mahmood, A.H. Gilani The in vivo antifungal activity of the aqueous extract from *Nigella sativa* seeds *Phytother. Res.* 2003; 17: 183-186
256. L. Kokoska, J. Havlik, I. Valterova, H. Sovova, M. Sajfrtova, I. Jankovska- Comparison of chemical composition and antibacterial activity of *Nigella sativa* seed essential oils obtained by different extraction methods *J. Food Prot.* 2008,71:2475-2480
257. B. Kouidhi, T. Zmantar, H. Jrah, Y. Souiden, K. Chaieb, K. Mahdouani, etal. Antibacterial and resistance-modifying activities of thymoquinone against oral pathogens *Ann. Clin. Microbiol. Antimicrob.* 2011; 10: 29
258. M.A. Randhawa In vitro antituberculous activity of thymoquinone, an active principle of *Nigella sativa* *J. Ayub Med. Coll. Abbottabad*, 2011, 23:78-81
259. A. Piras, A. Rosa, B. Marongiu, S. Porcedda, D. Falconieri, M.A. Dessi, etal. Chemical composition and in vitro bioactivity of the volatile and fixed oils of *Nigella sativa* L. extracted by supercritical carbon dioxide *Ind. Crop Prod.*, 2013, 46:317-323
260. H. Mahmoudvand, A. Sepahvand, S. Jahanbakhsh, B. Ezatpour, S.A. Aya-tollahi Mousavi Evaluation of antifungal activities of the essential oil and various extracts of *Nigella sativa* and its main component, thymoquinone against pathogenic dermatophyte strains *J. Mycol. Med.* 2014; 24: 155-161
261. E.I. Aboul-Ela Cytogenetic studies on *Nigella sativa* seeds extract and thymoquinone on mouse cells infected with schistosomiasis using karyotyping *Mutat. Res.* 2002; 516: 11-17
262. K.M. Fararh, Y. Shimizu, T. Shiina, H. Nikami, M.M. Ghanem, T. Takewaki Thymoquinone reduces hepatic glucose production in diabetic hamsters *Res. Vet. Sci* 2005; 79: 219-223
263. A. Mahgoub Thymoquinone protects against experimental colitis in rats *Toxicol. Lett.* 2003;143:133-143
264. M. Kanter, H. Demir, C. Karakaya, H. Ozbek Gastroprotective activity of *Nigella sativa* L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats *World J. Gastroenterol.* 2005;11: 6662-6666
265. A. Kahraman, N. Erkasap, T. Köken, M. Serteser, F. Aktepe, S. Erkasap The antioxidative and antihistaminic properties of quercetin in ethanol-induced gastric lesions *Toxicology*, 2003;183: 133-142
266. S.C. El-Saleh, O.A. Al-Sagair, M.I. Al-Khalaf Thymoquinone and *Nigella sativa* oil protection against methionine-induced hyperhomocysteinemia in

- rats *Int. J. Cardiol.*2004;93: 19-23
- 268.M. ElGazzar, R. ElMezayen, J.C. Marecki, M.R. Nicolls, A. Canastar, S.C. DreskinAnti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation *Int. Immunopharmacol.*2006;6:1135-1142
- 268.M.M. Khattab, M.N. NagiThymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats *Phytother. Res.*2007;21:410-414
- 269.Enomoto S,Asano R, Iwahari Y et al. Hematological studies on black cumin oil from the seeds of *Nigella Sativa L.* *Biol Phatma Bull* 2001;24.307-310
- 270.M.ElGazzar, R.ElMezayen, J.C. Marecki, M.R. Nicolls, A. Canastar, S.C. DreskinAnti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation *Int. Immunopharmacol.*2006;6: 1135-1142
- 271.M.El Gazzar, R. ElMezayen, M.R. Nicolls, J.C. Marecki, S.C. DreskinDown-regulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma *Biochim. Biophys. Acta*, 2006;1760:1088-1095
- 272.Marbacher S, Fandino J, Kitchen ND. Standard intracranial in vivo animal models of delayed cerebral vasospasm. *Br J Neurosurg.* 2010; 24: 415-34
- 273.Barry KJ, Gogjian MA, Stein BM. Small animal model for investigation of subarachnoid hemorrhage and cerebral vasospasm. *Stroke.* 1979; 10: 538-41.
- 274.Solomon RA, Antunes JL, Chen RY, et al. Decrease in cerebral blood flow in rats after experimental subarachnoid hemorrhage: a new animal model. *Stroke.* 1985; 16: 58-64.